Antithrombotic dose: some observations from published clinical trials

Research output: Contribution to journalArticlepeer-review

Standard

Antithrombotic dose : some observations from published clinical trials. / Dimmitt, Simon; Floyd, Christopher; Ferner, Robin.

In: British Journal of Clinical Pharmacology, Vol. 85, No. 10, 01.10.2019, p. 2194-2197.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Dimmitt, Simon ; Floyd, Christopher ; Ferner, Robin. / Antithrombotic dose : some observations from published clinical trials. In: British Journal of Clinical Pharmacology. 2019 ; Vol. 85, No. 10. pp. 2194-2197.

Bibtex

@article{cf096a5cd82b4dbaa8e24f6a8f1b7371,
title = "Antithrombotic dose: some observations from published clinical trials",
abstract = "The clinical doses of antithrombotics-antiplatelet and anticoagulant agents-need to balance efficacy and safety. It is not clear from the published literature how the doses currently used in clinical practice have been derived from preclinical and clinical data. There are few large randomised controlled trials (RCTs) that compare outcomes with different doses vs placebo. For newer antithrombotics, RCT doses appear to have been chosen to maximise the probability of demonstrating noninferiority when compared to established agents such as warfarin or clopidogrel. Data from RCTs show that aspirin is an effective antithrombotic at doses below 75 mg daily, and that direct oral anticoagulants reduce the risk of stroke in patients with coronary disease at doses 1/4 of those recommended in atrial fibrillation. Lower doses than those currently recommended are safer and still maintain substantial efficacy.",
author = "Simon Dimmitt and Christopher Floyd and Robin Ferner",
note = "{\textcopyright} 2019 The British Pharmacological Society.",
year = "2019",
month = oct,
day = "1",
doi = "10.1111/bcp.13968",
language = "English",
volume = "85",
pages = "2194--2197",
journal = "British Journal of Clinical Pharmacology",
issn = "0306-5251",
publisher = "Wiley",
number = "10",

}

RIS

TY - JOUR

T1 - Antithrombotic dose

T2 - some observations from published clinical trials

AU - Dimmitt, Simon

AU - Floyd, Christopher

AU - Ferner, Robin

N1 - © 2019 The British Pharmacological Society.

PY - 2019/10/1

Y1 - 2019/10/1

N2 - The clinical doses of antithrombotics-antiplatelet and anticoagulant agents-need to balance efficacy and safety. It is not clear from the published literature how the doses currently used in clinical practice have been derived from preclinical and clinical data. There are few large randomised controlled trials (RCTs) that compare outcomes with different doses vs placebo. For newer antithrombotics, RCT doses appear to have been chosen to maximise the probability of demonstrating noninferiority when compared to established agents such as warfarin or clopidogrel. Data from RCTs show that aspirin is an effective antithrombotic at doses below 75 mg daily, and that direct oral anticoagulants reduce the risk of stroke in patients with coronary disease at doses 1/4 of those recommended in atrial fibrillation. Lower doses than those currently recommended are safer and still maintain substantial efficacy.

AB - The clinical doses of antithrombotics-antiplatelet and anticoagulant agents-need to balance efficacy and safety. It is not clear from the published literature how the doses currently used in clinical practice have been derived from preclinical and clinical data. There are few large randomised controlled trials (RCTs) that compare outcomes with different doses vs placebo. For newer antithrombotics, RCT doses appear to have been chosen to maximise the probability of demonstrating noninferiority when compared to established agents such as warfarin or clopidogrel. Data from RCTs show that aspirin is an effective antithrombotic at doses below 75 mg daily, and that direct oral anticoagulants reduce the risk of stroke in patients with coronary disease at doses 1/4 of those recommended in atrial fibrillation. Lower doses than those currently recommended are safer and still maintain substantial efficacy.

UR - http://www.scopus.com/inward/record.url?scp=85068511614&partnerID=8YFLogxK

U2 - 10.1111/bcp.13968

DO - 10.1111/bcp.13968

M3 - Article

C2 - 31050833

VL - 85

SP - 2194

EP - 2197

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

SN - 0306-5251

IS - 10

ER -